

Antisoma plc
West Africa House
Hanger Lane
Ealing
London W5 3QR
UK

Tel: +44 (0)20 8799 8200
Fax: +44 (0)20 8799 8201


e-mail: enquiries@antisoma.com
www.antisoma.com

RECEIVED

AUG -2 P 12:19
OFFICE OF INTERNATIONAL
CORPORATE FINANCE



Office of International Corporate Finance
Division of Corporate Finance
Mail Stop 3628
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
U.S.A.



Wednesday 26 July 2006

Ladies and Gentlemen:

Antisoma plc

Pursuant to Rule 12g3-2(b) under the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"), we hereby furnish you with certain documentation that we have made public or filed with the UK Listing Authority, the London Stock Exchange or the Registrar of Companies for England and Wales at Companies House or distributed to our shareholders and which is listed in Annex 1 to this letter.

These documents supplement the information previously provided with respect to Antisoma plc's request for exemption under Rule 12g3-2(b), which was established on November 21, 2005.

This information is being furnished with the understanding that such information and documents will not be deemed "filed" with the SEC or otherwise subject to the liabilities of Section 18 of the Exchange Act, and that neither this letter nor the furnishing of such documents and information shall constitute an admission for any purpose that Antisoma plc is subject to the Exchange Act.

Please do not hesitate to contact the undersigned at +44 20 8799 8200 in the United Kingdom if you have any questions.

Thank you for your attention.

Yours faithfully
For and on behalf Antisoma plc

Name: Simone Tinney
Title: Communication Assistant

PROCESSED

AUG 08 2006

THOMSON
FINANCIAL

Antisoma plc
West Africa House
Hanger Lane
Ealing
London W5 3QR
UK

Tel: +44 (0)20 8799 8200
Fax: +44 (0)20 8799 8201

e-mail: enquiries@antisoma.com
www.antisoma.com

Director shareholding



ANTISOMA

London, UK: 26 July 2006 – Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) was notified of an additional purchase today of Antisoma 1p ordinary shares by the following Director:

	Number of shares	Price/share	Total holding after purchase
Dale Boden	100,000	USD 0.28 (15.2p)	669,478*

* Mr Boden's total holding includes a beneficial interest totalling 638,469 ordinary Antisoma shares held by BF Capital, BFC III Ltd and by The Sentinel I Trust.

Enquiries:

Daniel Elger

Director of Communications

Antisoma plc

+44 (0)20 8799 8200

RECEIVED
2006 AUG -2 P 12:19
OFFICE OF INTERNATIONAL
CORPORATE FINANCE